indications for glp-1 A glimpse of the future: new molecules and GLP1 agonists 💡💉 GLP-1 and Incretin-Based Therapies in

[DOI] [PMC free article] [PubMed] [Google Scholar] 233

Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes

and a once-weekly subcutaneous tri-agonist 4

Equal and long-term access to treatment and cost-effectiveness One of the most challenging aspects of this new era in obesity management will be the long-term and equal access to the new obesity pharmacotherapies through funding from national health systems and/or private health insurances as there is lack of robust cost-effectiveness data

Heart 2012;98:408413

When a compounded GLP-1 program uses a 503B pharmacy, that typically signals stronger quality controls